Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Serious Herbal AEs Deemed Negligible; AHPA Urges Mandatory Reporting

This article was originally published in The Tan Sheet

Executive Summary

Mandatory adverse event reporting would not harm the botanicals industry because the number of serious adverse events for such products is extremely small, AHPA's board has concluded

You may also be interested in...



Firms Need To Commit More Time, Money To Industry Cause – DSEA’s Balbert

As dietary supplement firms participated in industry conventions in California, a Dietary Supplement Education Alliance board member sought to generate increased support for trade groups, but also raised the question of whether consolidated representation would be better for the industry

Firms Need To Commit More Time, Money To Industry Cause – DSEA’s Balbert

As dietary supplement firms participated in industry conventions in California, a Dietary Supplement Education Alliance board member sought to generate increased support for trade groups, but also raised the question of whether consolidated representation would be better for the industry

Firms Need To Commit More Time, Money To Industry Cause – DSEA’s Balbert

As dietary supplement firms participated in industry conventions in California, a Dietary Supplement Education Alliance board member sought to generate increased support for trade groups, but also raised the question of whether consolidated representation would be better for the industry

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS094630

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel